Company news
Shanghai Allist Pharmaceuticals Co. Ltd. Class A (SSE:688578) news
Shanghai Allist Pharmaceuticals Co. Ltd. Class A news releases on 6ix. Latest, Sep 22, 2026: "SHANGHAI ALLIST PHARMACEUTICALS CO., LTD"Announcement…
Press releases & updates
"SHANGHAI ALLIST PHARMACEUTICALS CO., LTD"Announcement on Voluntary Disclosure of the Acceptance of Marketing Application for a New Indication of Furmonertinib Mesilate Tablets
September 21, 2026
"SHANGHAI ALLIST PHARMACEUTICALS CO., LTD."Announcement on Participating in the 2026 Semi-annual Collective Performance Briefing for the STAR Market Innovative Drug Industry
September 7, 2026
"SHANGHAI ALLIST PHARMACEUTICALS CO., LTD."Announcement on Implementation of Dividend Distribution for the First Half of 2026
August 26, 2026
"SHANGHAI ALLIST PHARMACEUTICALS CO., LTD."Special Report on the Deposit, Management and Actual Use of Raised Funds for the First Half of 2026
August 19, 2026
"SHANGHAI ALLIST PHARMACEUTICALS CO., LTD."Announcement on Voluntary Disclosure of Semi-annual Performance Forecast for 2026
July 16, 2026
"SHANGHAI ALLIST PHARMACEUTICALS CO., LTD."Announcement on Abnormal Fluctuations in Stock Trading
July 3, 2026
Announcement on Implementation of Dividend Distribution for 2025
May 25, 2026
Announcement on Resolutions of the 2025 Annual General Meeting
May 13, 2026
Announcement on Voluntary Disclosure of Obtaining of Approval Notice for the Drug Clinical Trial of Newly Approved Indication of Furmonertinib Mesylate Tablets
April 29, 2026
Notice on Convening the 2025 Annual General Meeting
April 22, 2026
Announcement on Convening Performance and Cash Dividend Briefing for 2025 and Q1 2026
April 20, 2026
Announcement on Voluntary Disclosure of Earnings Preannouncement for Q1 2026
March 3, 2026
Announcement on Preliminary Earnings Estimate for 2025
February 26, 2026
Announcement on Voluntary Disclosure of Progress in Drug Registration for Second-Line Treatment of EGFR Exon 20 Insertion Mutation NSCLC in the Priority Review Process
February 3, 2026
Announcement on Expected Increase in Performance for 2025
January 28, 2026
Announcement on Voluntary Disclosure of Inclusion of Furmonertinib Mesylate Tablets for EGFR PACC-mutant NSCLC First-line Treatment in the Proposed Breakthrough Therapy Designation
December 25, 2025
Announcement on Using Partial Temporarily Idle Raised Funds for Cash Management
December 15, 2025
Announcement on Voluntary Disclosure of the Inclusion of the Company’s Innovative Drugs in the Updated National Medical Insurance Catalog
December 7, 2025
Announcement on Completing Term Change and Election of Board of Directors and Appointing Senior Management Members and Securities Affairs Representative
November 27, 2025
Announcement on Attending Three-Quarter Report Collective Performance Briefing of Listed Companies in Shanghai Jurisdiction in 2025
November 4, 2025
Report for Q3 2025
October 28, 2025
Announcement on Result of Shareholding Reduction by Shareholder
September 24, 2025
Indicative Announcement on Change in Equity of Shareholder Reaching 1% Scale
September 12, 2025
Announcement on Attending Collective Performance Briefing for Innovative Drug Industry on Semi-annual SSE STAR Market 2025
September 8, 2025
Announcement on Implementation of Semi-annual Dividend Distribution for 2025
September 2, 2025
Special Report on Semi-annual Deposit and Actual Use of Raised Funds in 2025
August 26, 2025
Announcement on Shareholding Reduction Plan for Shareholders
August 8, 2025
Announcement on Voluntary Disclosure of Proposed Inclusion of Furmonertinib Mesylate Tablets for Second-Line Treatment of EGFR Exon 20 Insertion Mutation NSCLC in the Priority Review Process
July 9, 2025
Announcement on Voluntary Disclosure of Obtaining the 25th China Patent Gold Award
June 8, 2025
Announcement on Implementation of Dividend Distribution for 2024
May 22, 2025
Announcement on Resolution of the 2024 Annual General Meeting
May 14, 2025
Report for Q1 2025
April 23, 2025
Announcement on Preliminary Earnings Estimate for 2024
February 25, 2025
Annual Earnings Preannouncement for 2024
January 20, 2025
Announcement on Voluntary Disclosure of Obtaining Notice of Drug Clinical Trial Approval for New Indications of Furmonertinib
January 17, 2025
Announcement on Resolution of the 10th Meeting of the 2nd Board of Supervisors
December 16, 2024
Announcement on Resolution of the 1st Extraordinary General Meeting in 2024
November 26, 2024
Announcement on Accounting Firm Change
November 8, 2024
Announcement on Attending Collective Q3 Report Performance Briefing of Listed Companies in Shanghai Jurisdiction in 2024
November 5, 2024
Announcement on the Result of Shareholding Reduction by Shareholders and the Change in Equity Reaching 1%
October 29, 2024
Report for Q3 2024
October 24, 2024
Announcement on Change of Sponsor Representative
October 9, 2024
Announcement on Voluntary Disclosure of Obtaining the Drug Clinical Trial Approval Notification for AST2303 Tablets
September 23, 2024
Announcement on Attending Semi-annual Collective Performance Briefing 2024 for Pharmaceutical and Biological Products Companies on STAR Market
September 6, 2024
Announcement on Signing Drug Technology License and Development Agreement with Jacobio
August 30, 2024
Announcement on the Implementation of Semi-annual Dividend Distribution in 2024
August 29, 2024
Semi-annual Report 2024
August 20, 2024
Announcement on the Plan to Reduce Shares Held by the Company's Shareholders
July 19, 2024
Announcement on Receipt of Notice of Arbitration
July 9, 2024
Announcement on Resignation of Non-independent Director
June 19, 2024